Page 12 - MRS Abstracts March 2023

Comorbidities Cardiac related CKD
DM
Other comorbidities
214 (53.6) 114 (28.6) 68 (17.0) 263 (65.9)
190 (47.6) 101 (25.3) 59 (14.8) 223 (55.9)
24 (6.0) 13 (3.3) 9 (2.3) 40 (10.0)
2.70 (1.57- 4.62) 1.99 (1.04- 3.79) 1.51 (0.71- 3.79) 1.65 (0.98- 2.78)
<0.001 0.035 0.280 0.012
Evidence of gout on USS/X-ray
Yes No
194 (48.6) 205 (51.4)
164 (41.1) 164 (41.1)
30 (7.5) 41 (10.3)
1.33 (0.78- 2.27)
0.291
Multimorbidity Yes
No
183 (45.9) 189 (47.4)
166 (41.6) 164 (41.1)
17 (4.3) 25 (6.3)
2.71 (1.57- 4.69)
<0.001
GP Follow up Yes
No
351 (87.9) 48 (12.0)
289 (72.4) 31 (7.8)
62 (15.5) 17 (4.2)
1.19 (1.13- 1.25)
<0.001
N/n: Sample size, OR: Odd ratio, CI: Confidence interval, IQR: Interquartile range, ꭕ2: Chi-square test, Mann WU: Mann Whitney U test, M: Male, F: Female, SUA: Serum uric acid, CKD: Chronic kidney disease, DM: Diabetes mellitus, USS: Ultrasound scan, *Median (Interquartile Range) for continuous variables, P-value < 0.05 is significant. Multimorbidity: the presence of 2 or more comorbidities. Other comorbidity was defined as other conditions in the patient different from the defined comorbidities.
Table 2 Predictors of all causes of hospitalisation in patients with gout (Binary logistics regression)
Variates
Age
Gender (reference Female) Multimorbidity (reference no) Tophus at presentation (reference no)
CKD (reference no)
SUA now
Other comorbidities (reference no)
OR (95% CI)
0.10 (0.97-1.02) 1.19 (0.53-2.68) 0.99 (0.23-2.97) 0.25 (0.12-0.52)
1.01 (0.38-2.63) 1.15 (1.06-1.24) 3.48 (1.63-7.42)
P-value
0.746 0.680 0.768 <0.001
0.992
0.002 0.001